News

ACHN

Seven Stocks to be Thankful For

Daniel Banas | Equities.com |

With delicious aromas wafting from the kitchen and holiday cheer all around, there’s nothing better than spending Thanksgiving at home among loved ones. However, if you’re stranded at


Conatus (CNAT) Surges Amid Hepatitis C Fervor

Remy Merritt | Equities.com |

Conatus Pharmaceuticals (CNAT) continues the trend of huge pharmaceutical and biotechnology movers this week, peaking on June 11 at an intraday high of $9.87 a share. The past week has seen huge


Could Achillion (ACHN) be the Biggest Beneficiary of Merck's (MRK) Idenix (IDIX) Purchase?

Andrew Klips | Equities.com |

Shares of Achillion Pharmaceuticals (ACHN) are roaring ahead in Tuesday action after the U.S. Food and Drug Administration lifted its clinical hold on the Achillion’s experimental drug


Achillion (ACHN) Soars After FDA OKs Resumption of Trial for Hepatitis C Drug

Eileen Meng Lu | Equities.com |

The Food and Drug Administration (FDA) lifted the clinical hold on Achillion Pharmaceuticals Inc.'s (ACHN) study for experimental hepatitis C drug on June 10, eight months after


Catching Hepatitis: Why Merck (MRK) Was Willing to Break the Bank for Idenix (IDIX)

Joel Anderson | Equities.com |

Monday saw a major tectonic shift in the market for biotech companies. Or, rather, the tectonic shift happened some time ago; Monday was the day a major earthquake finally rippled across the stock


Idenix Pharmaceuticals (IDIX) Takes Off Depite Q3 Loss in Potential Short Squeeze

Joel Anderson | Equities.com |

In a year that's already seen some major peaks and valleys for small-cap pharma Idenix Pharmaceuticals (IDIX) , the drama doesn't show signs of letting up. Idenix has jumped almost 45


Achillion Tanks on Dreary Outlook for Hep C Drug

Joel Anderson | Equities.com |

Shares in Achillion Pharmaceuticals (ACHN) were off over 50 percent at market open on Monday after the FDA maintained a hold on the company’s hepatitis C drug sovaprevir after market close


Stocks Under $10: Hold Rated Biomed/Genetics in the Medical Sector

Richard Suttmeier | Equities.com |

At www.ValuEngine.com we show that the Medical sector 10.6% overvalued with the Medical Biomed / Genetics 12.3% overvalued. All 16 stocks in today’s table have complete ValuEngine data and have


Achillion Shares Continue Upward March on Positive Drug News

Andrew Klips | Equities.com |

Shares of Achillion Pharmaceuticals (ACHN) are on the rise again today after reporting positive results for its hepatitis C (HCV) drug ACH-3102, a second-generation pan-genotypic NS5A inhibitor.


Equities Sector Coverage: Stocks Inch Higher on Housing Boost

Sector Recap | Equities.com |

Housing Starts rose a less than expected 2.3% to 750,000 units annualized in August. Building Permits fell by 1.0%. Existing Home Sales rose 7.8% in August to an annual rate of 4.82 million, the


Sponsored Financial Content

Market Movers